Gilead's new drug keeps 56 pct of lymphoma trial patients alive - Reuters

Financial Times

Gilead's new drug keeps 56 pct of lymphoma trial patients alive Reuters Dec 10 (Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on ... CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaMarkets Insider Gilead dispels doubts with Car-T cancer drug trial resultsFinancial Times all 7 news articles »

from Health - Google News http://ift.tt/2AUBP0c